Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment

Author:

Hong Hyeyeon1ORCID,Cho Minjoo2,Lim Chaeyeon1,Choi Won‐Mook1ORCID,Lee Danbi1,Shim Ju Hyun1ORCID,Kim Kang Mo1ORCID,Lim Young‐Suk1ORCID,Lee Han Chu1ORCID,Choi Jonggi1ORCID

Affiliation:

1. Department of Gastroenterology, Liver Center, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

2. Department of Internal Medicine, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

Abstract

SummaryBackgroundPatients with chronic hepatitis B (CHB) on nucleos(t)ide analogues (NUCs) often experience renal function decline. Conflicting results regarding the impact of NUC use and renal function have recently been reported.AimTo examine longitudinal changes in renal function according to the NUC treatment type compared with untreated patientsMethodsFrom 2014 to 2022, we retrospectively analysed 10,642 patients with CHB. The primary outcome was chronic kidney disease (CKD) progression, which was defined as a minimum one‐stage elevation. We applied propensity score (PS) matching for outcome comparisons.ResultsIn the PS‐matched cohort of 1996 pairs, the NUC‐treated group (7.6/100 person‐years [PYs]) had a significantly higher CKD progression risk than the untreated group (4.4/100 PYs), with a hazard ratio (HR) of 1.70 (p < 0.001). The tenofovir disoproxil fumarate (TDF)‐treated group (7.9/100 PYs) showed a 1.76‐fold increased CKD progression risk compared with the untreated group (4.5/100 PYs) in the PS‐matched cohort (p < 0.001). Both the entecavir‐ and tenofovir alafenamide (TAF)‐treated groups showed CKD progression risks comparable to those of the untreated group in the PS‐matched cohorts of 755 and 426 pairs, respectively (p = 0.132 and p = 0.120, respectively). No significant CKD progression risk was found between the entecavir‐ (6.0/100 PYs) and TAF‐treated (5.2/100 PYs) groups in the PS‐matched cohort of 510 pairs (p = 0.118).ConclusionsNUC‐treated patients, especially those on TDF, faced a higher CKD progression risk than untreated patients. Entecavir‐ and TAF‐treated patients had comparable CKD progression risks to untreated patients. No difference was observed between entecavir and TAF in the risk of CKD progression.

Funder

Korea Health Industry Development Institute

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3